title: [Description of erlotinib-related skin effects management in France. Results of the PRECEDE study].
abstract: BACKGROUND
  Dermatological effects are among the most frequent side-effects in patients receiving erlotinib (Tarceva). However, there no official recommendations on the preventive or curative management of those erlotinib-related skin effects (ERSE). The "Prise En Charge des Effets Dermatologiques sous Erlotinib" (PRECEDE) study was designed to study how ERSE are being managed in France.
  
  
  METHODS
  The PRECEDE study is an observational retrospective study which included every nonsmall cell lung cancer patients treated with erlotinib in seven cancer centers in France from January 2005 to December 2007. Data related to preventive or curative treatment of ERSE were collected from the medical files of the patients.
  
  
  RESULTS
  Two hundred and thirty-four patients were included; 48.7% of them had been delivered information on the potential occurrence of ERSE and 15.8% of those 234 patients had had prescription of drugs to be taken in case of ERSE, while 65.0% presented with ERSE which resolved in the majority of cases (86.2% of the patients), either spontaneously or under treatment. In the 85 patients in whom treatment was successful, 178 drug prescriptions comprising 35 different drugs were recorded.
  
  
  CONCLUSIONS
  ERSE are frequent but regress in most cases, spontaneously or under treatment. However, there is still a wide variety of drugs used. This demonstrates that there is a need for recommendations on the management of ERSE in order to prevent and treat this erlotinib-related effect.
authors.affiliation: ICAR-service de néphrologie, hôpital Pitié-Salpêtrière, 83, boulevard de l'Hôpital, 75013 Paris, France. nicolas.janus@psl.aphp.fr
authors.forename: N
authors.initials: N
authors.lastname: Janus
authors.forename: V
authors.initials: V
authors.lastname: Launay-Vacher
authors.forename: C
authors.initials: C
authors.lastname: Robert
authors.forename: P-J
authors.initials: PJ
authors.lastname: Souquet
authors.forename: C
authors.initials: C
authors.lastname: Mateus
authors.forename: B
authors.initials: B
authors.lastname: Dreno
authors.forename: G
authors.initials: G
authors.lastname: Deray
authors.forename: J-F
authors.initials: JF
authors.lastname: Morere
authors.forename: G
authors.initials: G
authors.lastname: Deplanque
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology*; D000069347:Erlotinib Hydrochloride; D005260:Female; D005602:France; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride